Candonilimab

Phase 2Monoclonal antibody

SShi Ming

Candonilimab is one of 97 small molecule programs targeting Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentRecruiting

Efficacy and SafetyRecruiting

Biliary CancerRecruiting

TreatmentPhase 2

Recruiting

Efficacy and SafetyPhase 2

Recruiting

Biliary CancerPhase 2

Recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

4 2

Dexilant

Takeda

Preclinical

2 3

Candonilimab

SShi Ming

Phase 2

1 4

Foscavir

CClinigen, Inc.

Preclinical

6 5

Valium

Akero Therapeutics

Preclinical

2 6

Lotemax

PPharmos

Preclinical

1 7

Reminyl

WWim Janssens

Preclinical

1 8

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Clomid

Ferring

Preclinical

1 10

Norpramin

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Efficacy and Safety

NCT05926700

Clinical

Trials by Indication[1]

Bevacizumab2 trials

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Unknown status·SShi Ming·Phase 2·NCT05760599·30 enrolled

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Withdrawn·SShi Ming·Phase 2·NCT05886257

Efficacy and Safety1 trial

Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05926700·27 enrolled

Biliary Cancer1 trial

Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Recruiting·WWest China Hospital·Phase 2·NCT05978609·65 enrolled

Treatment1 trial

Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM

Recruiting·JJin-hong Chen·Phase 2·NCT06455254·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Candonilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Candonilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Candonilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shi Ming company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: SShi Ming

Candonilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Bevacizumab2 trials

Efficacy and Safety1 trial

Biliary Cancer1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News